Skip to main content

Endothelial-Derived CCL7 Promotes Macrophage Polarization and Aggravates Septic Acute Lung Injury via CCR1-Mediated STAT1 Succinylation.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)2025-08-04PubMed
Total: 84.0Innovation: 9Impact: 0Rigor: 0Citation: 0

Summary

Endothelial CCL7 drives CCR1+ macrophage metabolic reprogramming and M1 polarization via KAT2A-dependent STAT1 succinylation, amplifying inflammation in septic ALI. Endothelial-specific CCL7 inhibition reduced lung injury severity in sepsis models, nominating the CCL7–CCR1–KAT2A–STAT1 axis as a therapeutic target.

Key Findings

  • Endothelial cells secrete CCL7 that induces metabolic reprogramming and M1 polarization of CCR1+ macrophages.
  • Endothelial-specific inhibition of CCL7 reduces the severity of septic acute lung injury in vivo.
  • CCL7–CCR1 signaling increases KAT2A expression, enhancing STAT1 succinylation and binding to promoters of glycolytic genes to drive inflammatory cascades.

Clinical Implications

CCR1 antagonists or strategies to modulate endothelial CCL7 release and STAT1 succinylation could attenuate inflammatory lung injury in sepsis, informing target selection for translational studies.

Why It Matters

This study reveals an epigenetic-metabolic mechanism linking endothelial chemokine signaling to macrophage polarization and lung injury, identifying druggable nodes (CCR1, KAT2A, STAT1 succinylation).

Limitations

  • Preclinical murine models without human clinical validation
  • Abstract truncation limits details on knockout phenotypes and breadth of experimental systems

Future Directions

Test CCR1 antagonists or KAT2A/STAT1-succinylation modulators in sepsis ALI models and evaluate endothelial CCL7/CCR1 signatures in human cohorts to enable biomarker-guided trials.

Study Information

Study Type
Cohort
Research Domain
Pathophysiology
Evidence Level
V - Preclinical mechanistic study in animal models and cells
Study Design
OTHER